Pieris Pharma reports Q4 and FY15 results

• Pieris Pharmaceuticals (NASDAQ:PIRS) Q4 results: Revenues: $2.1M (-36.4%); R&D Expense: $2.9M (+26.1%); SG&A: $1.8M (-37.9%); Operating Loss: ($2.6M) (-36.8%); Net Loss: ($2.9M) (+31.0%); Loss Per Share: ($0.07) (+66.7%).
• FY2015 results: Revenues: $2.9M (-46.3%); R&D Expense: $8.2M (+46.4%); SG&A: $8.4M (+20.0%); Operating Loss: ($13.7M) (-90.3%); Net Loss: ($14.1M) (-43.9%); Loss Per Share: ($0.41) (+42.3%); Quick Assets: $29.3M (+58.4%).
• No guidance given.